VRCA Verrica Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1660334 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY370.2%
TTM net income YoY76.6%
TTM EPS YoY88.6%
Revenue 3-yr CAGR57.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-34.2%
Net margin-50.3%
FCF margin—
EBITDA margin-33.9%
Returns
ROE-240.4%
ROA-35.3%
ROIC (approx.)—
Asset turnover0.70x
Leverage & solvency
Liabilities / assets47.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-1.57x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.91M | $5.86M | $5.02M | $5.09M | $14.34M | $12.70M | $3.44M | $344,000 |
| Cost of revenue | — | — | — | — | — | — | $700,000 | $800,000 |
| Gross profit | — | — | — | — | — | — | $2.74M | -$456,000 |
| R&D expense | $7.58M | $6.03M | $3.86M | $2.52M | $2.21M | $1.85M | $2.28M | $1.17M |
| SG&A expense | $10.36M | $10.35M | $9.99M | $8.12M | $9.40M | $8.85M | $8.85M | $9.88M |
| Operating income | -$12.17M | -$13.10M | -$9.71M | -$7.19M | $1.63M | $1.51M | -$8.13M | -$11.41M |
| Interest expense | $285,000 | $164,000 | $160,000 | $1.31M | $2.09M | $2.13M | $2.20M | $2.35M |
| Net income | -$12.41M | -$13.15M | -$9.68M | -$8.07M | -$274,000 | $204,000 | -$9.74M | -$16.20M |
| EBITDA | -$12.16M | -$13.08M | -$9.70M | -$7.18M | $1.65M | $1.55M | -$8.08M | -$11.36M |
| EPS (basic) | -0.58 | -0.62 | -0.45 | — | -0.03 | 0.02 | -1.03 | — |
| EPS (diluted) | -0.58 | -0.62 | -0.45 | — | -0.03 | 0.02 | -1.03 | — |
| Weighted avg. shares (diluted) | 21.31M | 21.31M | 21.31M | — | 9.49M | 9.49M | 9.48M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.39M | $11.20M | $20.60M | $30.15M | $21.10M | $15.40M | $29.59M | $46.33M |
| Receivables | $11.24M | $10.94M | $7.72M | $5.26M | $7.05M | $9.19M | $5.61M | $48,000 |
| Inventory | $2.80M | $2.71M | $1.97M | $2.24M | $2.30M | $2.52M | $2.46M | $2.46M |
| Current assets | $36.40M | $32.64M | $34.13M | $42.54M | $36.27M | $36.78M | $39.47M | $51.18M |
| PP&E, net | $167,000 | $177,000 | $191,000 | $209,000 | $225,000 | $315,000 | $537,000 | $589,000 |
| Total assets | $39.86M | $36.02M | $38.79M | $47.13M | $40.90M | $39.11M | $42.18M | $54.13M |
| Current liabilities | $21.93M | $22.44M | $16.22M | $16.44M | $28.91M | $29.22M | $29.40M | $29.01M |
| Short-term debt | — | — | — | $0 | $12.46M | $12.67M | $12.82M | $12.94M |
| Long-term debt | — | — | — | $0 | $21.62M | $24.58M | $27.81M | $30.98M |
| Total debt | — | — | — | $0 | $34.08M | $37.25M | $40.63M | $43.92M |
| Total liabilities | $45.84M | $31.71M | $22.73M | $22.39M | $57.94M | $56.59M | $60.75M | $63.99M |
| Shareholders' equity | -$5.97M | $4.31M | $16.05M | $24.74M | -$17.04M | -$17.48M | -$18.58M | -$9.86M |
| Net debt | — | — | — | -$30.15M | $12.98M | $21.86M | $11.04M | -$2.41M |
| Shares outstanding | 17.18M | 17.18M | 17.18M | 17.18M | 9.49M | 9.25M | 91.79M | 9.18M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.04M | -$9.28M | -$9.16M | -$4.59M | $9.69M | -$10.04M | -$12.68M | -$16.06M |
| Capital expenditure | — | — | — | $0 | $0 | — | — | $0 |
| Free cash flow | — | — | — | -$4.59M | $9.69M | — | — | -$16.06M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8,000 |
| Financing cash flow | $12.23M | -$126,000 | -$120,000 | $13.64M | -$3.98M | -$4.16M | -$4.06M | $39.43M |
| Depreciation & amortization | $10,000 | $15,000 | $17,000 | $14,000 | $21,807 | $45,000 | $52,000 | $54,000 |
| Stock-based compensation | $1.91M | $1.21M | $897,000 | $686,000 | $718,000 | $888,000 | $1.03M | $756,000 |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.